{
    "organizations": [],
    "uuid": "2901a99d5c2cc527bf5aa433c6e3e34698a2b3e5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-us-fda-says-permitted-marketing-of/brief-u-s-fda-says-permitted-marketing-of-dexcom-g6-integrated-continuous-glucose-monitoring-system-idUSFWN1R90SL",
    "ord_in_thread": 0,
    "title": "BRIEF-U.S. FDA Says Permitted Marketing Of Dexcom G6 Integrated Continuous Glucose Monitoring System",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 27 (Reuters) - Dexcom Inc:\n* U.S. FDA SAYS PERMITTED MARKETING OF THE DEXCOM G6 INTEGRATED CONTINUOUS GLUCOSE MONITORING (ICGM) SYSTEM\n* U.S. FDA SAYS AUTHORIZATION OF ICGM SYSTEM CLASSIFIES THIS NEW TYPE OF DEVICE IN CLASS II & SUBJECTS IT TO CERTAIN CRITERIA CALLED SPECIAL CONTROLS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-28T04:23:00.000+03:00",
    "crawled": "2018-03-28T19:08:10.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "dexcom",
        "inc",
        "fda",
        "say",
        "permitted",
        "marketing",
        "dexcom",
        "g6",
        "integrated",
        "continuous",
        "glucose",
        "monitoring",
        "icgm",
        "system",
        "fda",
        "say",
        "authorization",
        "icgm",
        "system",
        "classifies",
        "new",
        "type",
        "device",
        "class",
        "ii",
        "subject",
        "certain",
        "criterion",
        "called",
        "special",
        "control",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}